Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

BioLab Sciences Draws Warning Letter for Marketing Unapproved Biologics

  • Post author:PacConAdmin
  • Post published:September 22, 2022
  • Post category:Drug Industry Daily

Scottsdale, Ariz.-based BioLab Sciences has received an FDA warning letter for selling human tissue products without approved Biologics License Applications and for persistent deviations from current good manufacturing practice (cGMP)…

Continue ReadingBioLab Sciences Draws Warning Letter for Marketing Unapproved Biologics

Cancer AdComm Votes No on Spectrum’s Pozenveo for Orphan Disease Lung Cancer

  • Post author:PacConAdmin
  • Post published:September 22, 2022
  • Post category:Drug Industry Daily

Spectrum Pharmaceutical’s experimental cancer drug Pozenveo (poziotinib) got the thumbs down from the FDA’s Oncologic Drugs Advisory Committee (ODAC) in a vote of nine to four yesterday. Source: Drug Industry…

Continue ReadingCancer AdComm Votes No on Spectrum’s Pozenveo for Orphan Disease Lung Cancer

Advisory Committee Oks First FDA-Regulated Fecal Microbiota Transplant

  • Post author:PacConAdmin
  • Post published:September 22, 2022
  • Post category:Drug Industry Daily

The FDA’s Vaccines and Related Biological Products Advisory Committee agreed yesterday — somewhat grudgingly — that Rebyota (RBX2660), Rebiotix’s standardized fecal microbiota suspension, is a safe and effective treatment for…

Continue ReadingAdvisory Committee Oks First FDA-Regulated Fecal Microbiota Transplant

Catalent’s Bloomington Facility Rapped for Multiple Quality Failures

  • Post author:PacConAdmin
  • Post published:September 21, 2022
  • Post category:Drug Industry Daily

Following a month-long inspection in August, the FDA reprimanded Catalent for numerous quality lapses observed at its Bloomington, Ind., plant — where the drugmaker has performed manufacturing activities for both…

Continue ReadingCatalent’s Bloomington Facility Rapped for Multiple Quality Failures

FDA Provides Guidance on Securing Samples for Generics and Biosilimars

  • Post author:PacConAdmin
  • Post published:September 21, 2022
  • Post category:Drug Industry Daily

Makers of generics and biosimilars who have a hard time obtaining the samples of the reference product they need to develop their alternative products can turn to the FDA for…

Continue ReadingFDA Provides Guidance on Securing Samples for Generics and Biosilimars

FDA Briefs AdComm on High Risk, Limited Benefit of Spectrum’s Pozenveo

  • Post author:PacConAdmin
  • Post published:September 21, 2022
  • Post category:Drug Industry Daily

In briefing documents, the FDA expressed four major concerns about Pozenveo (poziotinib), Spectrum Pharmaceutical’s experimental lung and breast cancer drug, ahead of today’s meeting of the FDA’s Oncologic Drugs Advisory…

Continue ReadingFDA Briefs AdComm on High Risk, Limited Benefit of Spectrum’s Pozenveo

FDA’s New Overdose Prevention Framework Leaves Many Unanswered Questions

  • Post author:PacConAdmin
  • Post published:September 21, 2022
  • Post category:Drug Industry Daily

In many ways, there are more questions than answers in the FDA’s long-awaited and recently published Overdose Prevention Framework. Source: Drug Industry Daily

Continue ReadingFDA’s New Overdose Prevention Framework Leaves Many Unanswered Questions

Lawsuits Pile Up for GSK and Others Over Zantac’s Potential Cancer Risk

  • Post author:PacConAdmin
  • Post published:September 20, 2022
  • Post category:Drug Industry Daily

At least 88 additional lawsuits have been filed in Delaware against GSK and former Zantac (ranitidine) owners Pfizer, Boehringer Ingelheim and Sanofi, alleging the heartburn drug increases users’ risk of…

Continue ReadingLawsuits Pile Up for GSK and Others Over Zantac’s Potential Cancer Risk

Amyndas Can Continue to Battle Zealand US Over Alleged Violation of Trade Secrets

  • Post author:PacConAdmin
  • Post published:September 20, 2022
  • Post category:Drug Industry Daily

In a win for Amyndas Pharmaceuticals, the U.S. District Court in Massachusetts has overturned a lower court ruling that had dismissed the company’s complaint of misappropriation of trade secret agreements…

Continue ReadingAmyndas Can Continue to Battle Zealand US Over Alleged Violation of Trade Secrets

Merck to Investigate a Lower Dose of Its HIV Drug

  • Post author:PacConAdmin
  • Post published:September 20, 2022
  • Post category:Drug Industry Daily

Merck has found a way forward for its stalled oral antiretroviral islatravir, using a lower, 0.75 mg dose in three newly launched phase 3 trials and in a previously paused…

Continue ReadingMerck to Investigate a Lower Dose of Its HIV Drug
  • Go to the previous page
  • 1
  • …
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.